Kolkata, West Bengal -- (SBWIRE) -- 09/16/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Groupon Inc (NASDAQ:GRPN), Freeport-McMoRan Copper & Gold Inc.(NYSE:FCX), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR).
Groupon Inc (NASDAQ:GRPN) stock decreased 0.56% to $11.69. The company on Sept. 4 announces a concert deal of epic proportions: A trip to Los Angeles to meet legendary, nine-time Grammy® Award-winning recording artist Sheryl Crow. The Groupon deal includes airfare for two to Los Angeles, hotel accommodations, dinner for two, private round-trip transportation between LAX and the hotel and between the hotel and the concert venue, two tickets to Sheryl Crow's Free and Easy Tour at The Greek Theater and two copies of Sheryl Crow's latest album, FEELS LIKE HOME, which is available everywhere on Sept. 10.
Should Investors Buy GRPN After Yesterday’s Jump? Find Out Here
Freeport-McMoRan Copper & Gold Inc.(NYSE:FCX) shares decreased 0.33% to $33.04. FCX’s stock was upgraded by research analysts at Barclays Capital from a “market weight” rating to an “overweight” rating in a report released on Sept. 9.
Additionally, the company ended force majeure on shipments from the Indonesian copper mine at Grasberg, the world’s second largest, an executive said on Sept. 2. Shipments from Grasberg are at normal levels, Rozik B. Soetjipto, the president-director at the company’s local unit, said in a text message today. Phoenix-based Freeport has yet to formally announce the lifting of the force majeure declared on June 12, which allowed it to miss deliveries following a tunnel accident. Freeport resumed some concentrate shipments in July.
How Should Investors Trade FCX After The Recent Volatility? Get Free Trend Analysis Here
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) shares declined 18.24% to $4.08. The company on Sept 6 announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules. The settlement agreement grants Wockhardt the right to begin selling a generic version of NUEDEXTA on July 30, 2026, or earlier under certain circumstances.
Additionally, the company announced that on September 3, 2013, the Company approved the grant of stock options to new employees to purchase a total of 69,600 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4).
Is AVNR A Good Buy After The Recent Price Movement? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)